ArticleJournal of Alzheimer's disease : JAD2019
Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives.
Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Meta-analysis of the effects of dance- and movement-based kinesthetic games on cognitive function in older adults with cognitive impairment (CI) under different intervention periods.Aging clinical and experimental research · 2025Pooled it
- Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Pooled it
- Angiotensin II-Stimulating Antihypertensive Medications and Dementia-Related Neuropathology.JAMA network open · 2026Article
- Associations of Dietary Decanoic Acid Intake With Cognitive Function in the Elderly and the Mediating Effects of Hypertension and Diabetes: An Analysis From NHANES 2011-2014.Brain and behavior · 2026Article
- From Cerebrovascular Injury to Vascular Cognitive Impairment and Dementia: Therapeutic Potential of Stem Cell-Derived Extracellular Vesicles.Biomedicines · 2026Review
- EEG biomarkers in Alzheimer's and prodromal Alzheimer's: a comprehensive analysis of spectral and connectivity features.Alzheimer's research & therapy · 2024Article
- Associations of renin-angiotensin system inhibitor use with brain insulin signaling and neuropathology.Annals of clinical and translational neurology · 2024Article
- Angiotensin Receptor Blockers and Cognition: a Scoping Review.Current hypertension reports · 2024Article
- Review
- Association of vascular and degenerative brain pathologies and past medical history from the National Alzheimer's Coordinating Center Database.Journal of neuropathology and experimental neurology · 2023Article
- Angiotensin II Receptor Blockers Reduce Tau/Aß42 Ratio: A Cerebrospinal Fluid Biomarkers' Case-Control Study.Pharmaceutics · 2023Article
- The use of angiotensin receptor blockers in dementia prevention.Dementia & neuropsychologia · 2023Article
- Angiotensin Receptor Blockers and Dementia Prevention: Do Not RAS to a Conclusion Yet.Hypertension (Dallas, Tex. : 1979) · 2022Article
- Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimer's Disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Extracranial carotid atherosclerosis is associated with increased neurofibrillary tangle accumulation.Journal of vascular surgery · 2022Observational
- ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.Acta neuropathologica · 2020Article
- Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation.Alzheimer's & dementia (New York, N. Y.) · 2020Article
- Association of combination statin and antihypertensive therapy with reduced Alzheimer's disease and related dementia risk.PloS one · 2020Article
- Warfarin Versus Non-Vitamin K Inhibitors Medications and Cognitive Disease Progression in Atrial Fibrillation.The Journal of cardiovascular nursingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIndividuals taking renin angiotensin system (RAS) acting antihypertensives exhibit slower cognitive decline and are less likely to progress from mild cognitive impairment (MCI) to Alzheimer's disease (AD), but the mechanism remains unclear.
objectiveWe tested the hypothesis that individuals taking RAS acting antihypertensives exhibit less AD-related neuropathology and slower disease progression than individuals taking non-RAS acting antihypertensives.
methodParticipants included 83 individuals with MCI who were taking an antihypertensive at baseline, had at least two follow-up visits, and had postmortem neuropathological data. Participants were old (M = 83.1 years), 32% male, well educated (M = 15.7 years), and 9.2% Black.
resultsRAS medication users (N = 38) were less likely to progress to AD than non-RAS users (N = 45). RAS users exhibited fewer neurofibrillary tangles than non-RAS users in the hippocampal CA1 region (p < 0.01), entorhinal cortex (p = 0.03), and the angular gyrus, inferior temporal, mid-frontal cortex, and superior frontal (p = 0.01).
conclusionPrevention or clearance of neurofibrillary tangles represents a mechanism by which RAS medications may slow disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.